1
|
Bennett P, Williamson P, Taylor R. Review of Canine Lymphoma Treated with Chemotherapy-Outcomes and Prognostic Factors. Vet Sci 2023; 10:vetsci10050342. [PMID: 37235425 DOI: 10.3390/vetsci10050342] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Revised: 05/09/2023] [Accepted: 05/09/2023] [Indexed: 05/28/2023] Open
Abstract
While canine lymphoma is a relatively common and important disease seen by veterinarians, there are limited comprehensive reviews of the literature regarding the remission and survival times following chemotherapy, and the associated prognostic factors. This comprehensive thematic review covers the available veterinary literature covering treatment outcomes and identified prognostic factors. A lack of standardised approaches to evaluate and report the outcomes was identified, including factors that would alter the duration of responses by weeks, or occasionally months. After publication of the suggested reporting criteria, this has improved but is still not uniformly applied. The prognostic factors included for evaluation varied from as few as three to seventeen, with over 50 studies using only univariate analysis. Individual papers reported much longer outcomes than others, but assessing the outcomes overall, there has been minimal change over the last 40 years. This supports the belief that novel approaches for lymphoma therapy will be required to substantively improve outcomes.
Collapse
Affiliation(s)
- Peter Bennett
- The Sydney School of Veterinary Science, Faculty of Science, The University of Sydney, Camperdown, NSW 2006, Australia
- The University of Sydney Nano Institute, The University of Sydney, Camperdown, NSW 2006, Australia
| | - Peter Williamson
- The Sydney School of Veterinary Science, Faculty of Science, The University of Sydney, Camperdown, NSW 2006, Australia
| | - Rosanne Taylor
- The Sydney School of Veterinary Science, Faculty of Science, The University of Sydney, Camperdown, NSW 2006, Australia
| |
Collapse
|
2
|
Dékay V, Karai E, Füredi A, Szebényi K, Szakács G, Vajdovich P. P-Glycoprotein Activity at Diagnosis Does Not Predict Therapy Outcome and Survival in Canine B-Cell Lymphoma. Cancers (Basel) 2022; 14:cancers14163919. [PMID: 36010910 PMCID: PMC9405845 DOI: 10.3390/cancers14163919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Revised: 08/08/2022] [Accepted: 08/12/2022] [Indexed: 11/16/2022] Open
Abstract
Simple Summary Clinical experience in human and canine clinics shows that following initial response to treatment, drug-resistant cancer cells frequently evolve and eventually, most tumors become resistant to all available therapies. The most straightforward cause of therapy resistance is linked to cellular alterations that prevent drugs from acting on their target. Drug efflux mediated by the ABC transporter P-glycoprotein (P-gp) contributes to unfavorable treatment outcome in several human malignancies. Here, we characterize a large cohort of canine B-cell lymphoma patients followed for over 7 years. We show that the intrinsic P-gp activity of tumor cells characterized at the time of diagnosis is not predictive for therapy outcome. Our results highlight the complexity of clinical drug resistance mechanisms and suggests that the relevance of P-gp in acquired resistance should be further investigated by the continuous monitoring of tumor cells during treatment. Abstract Various mechanisms are known to be involved in the development of multidrug resistance during cancer treatment. P-glycoprotein (P-gp) decreases the intracellular concentrations of cytotoxic drugs by an energy-dependent efflux mechanism. The aim of this study was to investigate the predictive value of P-gp function based on the evaluation of P-gp activity in tumor cells obtained from canine B-cell lymphoma patients at diagnosis. P-gp function of 79 immunophenotyped canine lymphoma samples was determined by flow cytometry using the Calcein assay. Dogs were treated with either the CHOP or the L-CHOP protocol, a subset of relapsed patients received L-asparaginase and lomustine rescue treatments. Among the 79 dogs, the median overall survival time was 417 days, and the median relapse-free period was 301 days. 47 percent of the samples showed high P-gp activity, which was significantly higher in Stage IV cancer patients compared to Stage II + III and V. Whereas staging was associated with major differences in survival times, we found that the intrinsic P-gp activity of tumor cells measured at diagnosis is not predictive for therapy outcome. Further studies are needed to identify the intrinsic and acquired resistant mechanisms that shape therapy response and survival in B-cell canine lymphoma patients.
Collapse
Affiliation(s)
- Valéria Dékay
- Department of Clinical Pathology and Oncology, University of Veterinary Medicine Budapest, István Utca 2, H-1078 Budapest, Hungary
- Correspondence: (V.D.); (P.V.)
| | - Edina Karai
- Department of Clinical Pathology and Oncology, University of Veterinary Medicine Budapest, István Utca 2, H-1078 Budapest, Hungary
| | - András Füredi
- Institute of Enzymology, Research Center of Natural Sciences, Eötvös Loránd Research Network, Magyar Tudósok Körútja 2, H-1117 Budapest, Hungary or
- Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8A, A-1090 Vienna, Austria
| | - Kornélia Szebényi
- Institute of Enzymology, Research Center of Natural Sciences, Eötvös Loránd Research Network, Magyar Tudósok Körútja 2, H-1117 Budapest, Hungary or
- Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8A, A-1090 Vienna, Austria
| | - Gergely Szakács
- Institute of Enzymology, Research Center of Natural Sciences, Eötvös Loránd Research Network, Magyar Tudósok Körútja 2, H-1117 Budapest, Hungary or
- Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8A, A-1090 Vienna, Austria
| | - Péter Vajdovich
- Department of Clinical Pathology and Oncology, University of Veterinary Medicine Budapest, István Utca 2, H-1078 Budapest, Hungary
- Correspondence: (V.D.); (P.V.)
| |
Collapse
|
3
|
Celecoxib Prevents Doxorubicin-Induced Multidrug Resistance in Canine and Mouse Lymphoma Cell Lines. Cancers (Basel) 2020; 12:cancers12051117. [PMID: 32365663 PMCID: PMC7280963 DOI: 10.3390/cancers12051117] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2020] [Revised: 04/22/2020] [Accepted: 04/24/2020] [Indexed: 11/30/2022] Open
Abstract
Background: Treatment of malignancies is still a major challenge in human and canine cancer, mostly due to the emergence of multidrug resistance (MDR). One of the main contributors of MDR is the overexpression P-glycoprotein (Pgp), which recognizes and extrudes various chemotherapeutics from cancer cells. Methods: To study mechanisms underlying the development of drug resistance, we established an in vitro treatment protocol to rapidly induce Pgp-mediated MDR in cancer cells. Based on a clinical observation showing that a 33-day-long, unplanned drug holiday can reverse the MDR phenotype of a canine diffuse large B-cell lymphoma patient, our aim was to use the established assay to prevent the emergence of drug resistance in the early stages of treatment. Results: We showed that an in vitro drug holiday results in the decrease of Pgp expression in MDR cell lines. Surprisingly, celecoxib, a known COX-2 inhibitor, prevented the emergence of drug-induced MDR in murine and canine lymphoma cell lines. Conclusions: Our findings suggest that celecoxib could significantly improve the efficiency of chemotherapy by preventing the development of MDR in B-cell lymphoma.
Collapse
|
4
|
Boyé P, Floch F, Serres F, Segaoula Z, Hordeaux J, Pascal Q, Coste V, Courapied S, Bouchaert E, Rybicka A, Mazuy C, Marescaux L, Geeraert K, Fournel-Fleury C, Duhamel A, Machuron F, Ferré P, Pétain A, Guilbaud N, Tierny D, Gomes B. Randomized, double-blind trial of F14512, a polyamine-vectorized anticancer drug, compared with etoposide phosphate, in dogs with naturally occurring lymphoma. Oncotarget 2020; 11:671-686. [PMID: 32133044 PMCID: PMC7041934 DOI: 10.18632/oncotarget.27461] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2019] [Accepted: 01/13/2020] [Indexed: 12/12/2022] Open
Abstract
Purpose: F14512 is an epipodophyllotoxin derivative from etoposide, combined with a spermine moiety introduced as a cell delivery vector. The objective of this study was to compare the safety and antitumor activity of F14512 and etoposide phosphate in dogs with spontaneous non-Hodgkin lymphoma (NHL) and to investigate the potential benefit of F14512 in P-glycoprotein (Pgp) overexpressing lymphomas.
Experimental Design: Forty-eight client-owned dogs with intermediate to high-grade NHL were enrolled into a randomized, double-blind trial of F14512 versus etoposide phosphate. Endpoints included safety and therapeutic efficacy.
Results: Twenty-five dogs were randomized to receive F14512 and 23 dogs to receive etoposide phosphate. All adverse events (AEs) were reversible, and no treatment-related death was reported. Hematologic AEs were more severe with F14512 and gastrointestinal AEs were more frequent with etoposide phosphate. F14512 exhibited similar response rate and progression-free survival (PFS) as etoposide phosphate in the global treated population. Subgroup analysis of dogs with Pgp-overexpressing NHL showed a significant improvement in PFS in dogs treated with F14512 compared with etoposide phosphate.
Conclusion: F14512 showed strong therapeutic efficacy against spontaneous NHL and exhibited a clinical benefice in Pgp-overexpressing lymphoma superior to etoposide phosphate. The results clearly justify the evaluation of F14512 in human clinical trials.
Collapse
Affiliation(s)
- Pierre Boyé
- OCR (Oncovet-Clinical-Research), Loos, France.,Oncovet, Villeneuve d'Ascq, France.,Current address: Department of Small Animal Teaching Hospital, The Royal (Dick) School of Veterinary Studies and The Roslin Institute, University of Edinburgh, UK
| | | | - François Serres
- OCR (Oncovet-Clinical-Research), Loos, France.,Oncovet, Villeneuve d'Ascq, France
| | - Zacharie Segaoula
- OCR (Oncovet-Clinical-Research), Loos, France.,Université de Lille, JPARC - Centre de Recherche Jean-Pierre Aubert, Neurosciences et Cancer, Lille, France
| | | | | | | | | | | | | | | | | | | | | | - Alain Duhamel
- Université Lille, Santé Publique: Epidémiologie et Qualité des Soins, Lille, France
| | - François Machuron
- Université Lille, Santé Publique: Epidémiologie et Qualité des Soins, Lille, France
| | - Pierre Ferré
- Institut de Recherche Pierre Fabre, Toulouse, France
| | | | | | - Dominique Tierny
- OCR (Oncovet-Clinical-Research), Loos, France.,Oncovet, Villeneuve d'Ascq, France
| | - Bruno Gomes
- Institut de Recherche Pierre Fabre, Toulouse, France.,Current address: Hoffmann-La Roche, Switzerland
| |
Collapse
|
5
|
Hanot CC, Mealey KL, Fidel JL, Burke NS, White LA, Sellon RK. Development of prednisone resistance in naïve canine lymphoma: Longitudinal evaluation of NR3C1α, ABCB1, and 11β-HSD mRNA expression. J Vet Pharmacol Ther 2020; 43:231-236. [PMID: 31943234 DOI: 10.1111/jvp.12837] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2019] [Revised: 10/11/2019] [Accepted: 12/18/2019] [Indexed: 11/30/2022]
Abstract
Prednisone resistance develops rapidly and essentially universally when dogs with lymphoma are treated with corticosteroids. We investigated naturally occurring mechanisms of prednisone resistance in seven dogs with naïve multicentric lymphoma, treated with oral prednisone; four dogs were administered concurrent cytotoxic chemotherapy. Expression of NR3C1α, ABCB1 (formerly MDR1), 11β-HSD1, and 11β-HSD2 mRNA was evaluated in neoplastic lymph nodes by real-time RT-PCR. Changes of expression levels at diagnosis and at time of clinical resistance to prednisone were compared longitudinally using a Wilcoxon signed-rank test. Clinical resistance to prednisone was observed after a median of 68 days (range: 7-348 days) after initiation of treatment. Relative to pretreatment samples, prednisone resistance was associated with decreased NR3C1α expression in biopsies of all dogs with high-grade lymphoma (six dogs, p=.031); one dog with indolent T-zone lymphoma had increased expression of NR3C1α. Resistance was not consistently associated with changes in ABCB1, 11β-HSD1, or 11β-HSD2 expression. Decreased expression of the glucocorticoid receptor (NR3C1α) may play a role in conferring resistance to prednisone in dogs with lymphoma. Results do not indicate a broad role for changes in expression of ABCB1, 11β-HSD1, and 11β-HSD2 in the emergence of prednisone resistance in lymphoma-bearing dogs.
Collapse
Affiliation(s)
- Camille C Hanot
- Department of Veterinary Clinical Sciences, Washington State University, Pullman, WA, USA.,Medi-Vet SA, Lausanne, VD, Switzerland
| | - Katrina L Mealey
- Department of Veterinary Clinical Sciences, Washington State University, Pullman, WA, USA.,Program in Individualized Medicine (PrIMe), Washington State University, Pullman, WA, USA
| | - Janean L Fidel
- Department of Veterinary Clinical Sciences, Washington State University, Pullman, WA, USA
| | - Neal S Burke
- Program in Individualized Medicine (PrIMe), Washington State University, Pullman, WA, USA
| | - Laura A White
- Washington Animal Disease Diagnostic Laboratory, Pullman, WA, USA
| | - Rance K Sellon
- Department of Veterinary Clinical Sciences, Washington State University, Pullman, WA, USA
| |
Collapse
|
6
|
Thamm DH, Gustafson DL. Drug dose and drug choice: Optimizing medical therapy for veterinary cancer. Vet Comp Oncol 2019; 18:143-151. [PMID: 31487110 DOI: 10.1111/vco.12537] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2019] [Revised: 08/29/2019] [Accepted: 09/02/2019] [Indexed: 12/18/2022]
Abstract
Although novel agents hold great promise for the treatment of animal neoplasia, there may be room for significant improvement in the use of currently available agents. These improvements include altered dosing schemes, novel combinations, and patient-specific dosing or selection of agents. Previous studies have identified surrogates for "individualized dose intensity,", for example, patient size, development of adverse effects, and pharmacokinetic parameters, as potential indicators of treatment efficacy in canine lymphoma, and strategies for patient-specific dose escalation are discussed. Strategies for treatment selection in individual patients include conventional histopathology, protein-based target assessment (eg, flow cytometry, immunohistochemistry, and mass spectrometry), and gene-based target assessment (gene expression profiling and targeted or global sequencing strategies). Currently available data in animal cancer evaluating these strategies are reviewed, as well as ongoing studies and suggestions for future directions.
Collapse
Affiliation(s)
- Douglas H Thamm
- Flint Animal Cancer Center, Colorado State University, Fort Collins, Colorado.,Cell and Molecular Biology Graduate Program, Colorado State University, Fort Collins, Colorado.,Developmental Therapeutics Program, University of Colorado Comprehensive Cancer Center, Fort Collins, Colorado
| | - Daniel L Gustafson
- Flint Animal Cancer Center, Colorado State University, Fort Collins, Colorado.,Cell and Molecular Biology Graduate Program, Colorado State University, Fort Collins, Colorado.,Developmental Therapeutics Program, University of Colorado Comprehensive Cancer Center, Fort Collins, Colorado
| |
Collapse
|
7
|
Intile JL, Rassnick KM, Al-Sarraf R, Chretin JD. Evaluation of the Tolerability of Combination Chemotherapy with Mitoxantrone and Dacarbazine in Dogs with Lymphoma. J Am Anim Hosp Assoc 2019; 55:101-109. [PMID: 30653362 DOI: 10.5326/jaaha-ms-6878] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Combination chemotherapy can be an effective option for treating resistant lymphoma in dogs. This retrospective study examined the tolerability and efficacy of the combination of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (dacarbazine) (DTIC) in a population of dogs with lymphoma resistant to a doxorubicin-containing chemotherapy protocol. Mitoxantrone was administered at 5 mg/m2 IV over 10 min followed by DTIC at 600 mg/m2 IV over 5 hr, every 3 wk. All dogs were treated with prophylactic trimethoprim-sulfadiazine and metoclopramide. The frequency of grade 4 neutropenia was 18%, and 5% of dogs were hospitalized from sepsis. Gastrointestinal toxicity was uncommon. The overall response rate was 34% (15 of 44; 95% confidence interval 20-48%) for a median duration of 97 days (range 24-636 days, 95% confidence interval 44-150 days). Fourteen of 15 dogs who received mitoxantrone and DTIC as first rescue responded to treatment. Dogs who achieved complete remission to their initial L-asparaginase, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol were more likely to respond to mitoxantrone and DTIC (23 versus 11%, P = .035). The combination of mitoxantrone and DTIC is a safe treatment option for resistant lymphoma in dogs.
Collapse
Affiliation(s)
- Joanne L Intile
- From the Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina (J.L.I.); Veterinary Medical Center of Central New York, Syracuse, New York (K.M.R.); Animal Emergency and Referral Associates, Fairfield, New Jersey (R.A-S.); and VCA West Los Angeles Animal Hospital, Los Angeles, California (J.D.C)
| | - Kenneth M Rassnick
- From the Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina (J.L.I.); Veterinary Medical Center of Central New York, Syracuse, New York (K.M.R.); Animal Emergency and Referral Associates, Fairfield, New Jersey (R.A-S.); and VCA West Los Angeles Animal Hospital, Los Angeles, California (J.D.C)
| | - Renee Al-Sarraf
- From the Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina (J.L.I.); Veterinary Medical Center of Central New York, Syracuse, New York (K.M.R.); Animal Emergency and Referral Associates, Fairfield, New Jersey (R.A-S.); and VCA West Los Angeles Animal Hospital, Los Angeles, California (J.D.C)
| | - John D Chretin
- From the Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina (J.L.I.); Veterinary Medical Center of Central New York, Syracuse, New York (K.M.R.); Animal Emergency and Referral Associates, Fairfield, New Jersey (R.A-S.); and VCA West Los Angeles Animal Hospital, Los Angeles, California (J.D.C)
| |
Collapse
|
8
|
|
9
|
Transcriptome analysis of ABCB1, ABCG2 and the BCL2/BAX ratio in refractory and relapsed canine lymphomas under treatment and rescue protocol. ACTA VET-BEOGRAD 2018. [DOI: 10.2478/acve-2018-0002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Abstract
The main problems that cause unresponsiveness to an anti-neoplastic drug are the overexpression of drug resistant and anti-apoptotic proteins in tumor cells. In a rescue protocol we evaluated the ability of toceranib phosphate concurrent with lomustine (CCNU) or L-asparaginase and vincristine to decrease drug resistant and apoptotic proteins in relapsed and refractory canine lymphomas. The peripheral blood samples were collected before and after the rescue treatment from fourteen dogs that were refractory to cyclophosphamide-vincristine-prednisolone (COP) or COP-doxorubicin (CHOP) treatment and had recurrent multicentric lymphoma. The mRNA expression level of ABCB1, ABCG2, Bcl2 and Bax were determined by quantitative real-time PCR. The fold-change in ABCB1, ABCG2, Bcl2 and Bax mRNA levels were analyzed in correlation with the progression-free survival (PFS). After the rescue treatment, the ABCB1 and ABCG2 mRNA expression levels were 1.57- and 1.85-fold lower (p = 0.4 and p = 0.87), respectively, compared to pre-treatment. Bcl2/Bax ratio was numerically but not significantly decreased 1.02-fold (p = 0.74). The overall response rate of this protocol was 50% with a median PFS of 79 days (range 14-207 days). The low medians of relative expression levels of ABCB1, ABCG2 and Bcl2/Bax ratio group did not correlate with the clinical outcomes when compared to the high medians of relative expression levels, and likewise with the clinical stage, immunophenotype, histological grade and sub-stage. Therefore, the administration of a rescue drug with toceranib phosphate might be beneficial in refractory and relapsed canine lymphoma.
Collapse
|
10
|
Tanis JB, Mason SL, Maddox TW, Blackwood L, Killick DR, Amores-Fuster I, Harper A, Finotello R. Evaluation of a multi-agent chemotherapy protocol combining lomustine, procarbazine and prednisolone (LPP) for the treatment of relapsed canine non-Hodgkin high-grade lymphomas. Vet Comp Oncol 2018; 16:361-369. [PMID: 29380942 DOI: 10.1111/vco.12387] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2017] [Revised: 11/22/2017] [Accepted: 01/04/2018] [Indexed: 11/27/2022]
Abstract
The standard of care treatment for canine lymphoma is multi-agent chemotherapy containing prednisolone, cyclophosphamide, vincristine and an anthracycline such as doxorubicin (CHOP) or epirubicin (CEOP). Lomustine, vincristine, procarbazine, and prednisone (LOPP) has been evaluated as a rescue, with encouraging results; however, resistance to vincristine is likely in patients relapsing on CHOP/CEOP, and this agent may enhance LOPP toxicity without improving efficacy. The aim of this study was to evaluate responses to a modified-LOPP protocol that does not include vincristine (LPP) and is administered on a 21-day cycle. Medical records of dogs with high-grade multicentric lymphoma from 2012 to 2017 were reviewed. Dogs with relapsed lymphoma that received LPP as a rescue protocol were enrolled. Response, time from initiation to discontinuation (TTD) and toxicity of LPP were assessed. Forty-one dogs were included. Twenty-five dogs (61%) responded to LPP including 12 complete responses (CR) and 13 partial responses (PR). Responders had a significantly longer TTD (P < .001) compared to non-responders with 84 days for CR and 58 days for PR. Neutropenia was documented in 20 dogs (57%): 12 grade I to II, 8 grade III to IV. Thrombocytopenia was infrequent (20%): 5 grade I to II, 2 grade III to IV. Twelve dogs developed gastrointestinal toxicity (30%): 10 grade I to II and 2 grade III. Nineteen dogs had elevated ALT (59%): 9 grade I to II, 10 grade III to IV. Treatment was discontinued due to toxicity in 8 dogs (19%). The LPP protocol shows acceptable efficacy and toxicity-profile and minimizes in-hospital procedures.
Collapse
Affiliation(s)
- J-B Tanis
- Department of Small Animal Clinical Science, Institute of Veterinary Science, University of Liverpool, Liverpool, UK
| | - S L Mason
- Department of Veterinary Medicine, University of Cambridge, Cambridge, UK
| | - T W Maddox
- Department of Small Animal Clinical Science, Institute of Veterinary Science, University of Liverpool, Liverpool, UK
| | - L Blackwood
- Department of Small Animal Clinical Science, Institute of Veterinary Science, University of Liverpool, Liverpool, UK
| | - D R Killick
- Department of Small Animal Clinical Science, Institute of Veterinary Science, University of Liverpool, Liverpool, UK
| | - I Amores-Fuster
- Department of Small Animal Clinical Science, Institute of Veterinary Science, University of Liverpool, Liverpool, UK
| | - A Harper
- Department of Small Animal Clinical Science, Institute of Veterinary Science, University of Liverpool, Liverpool, UK
| | - R Finotello
- Department of Small Animal Clinical Science, Institute of Veterinary Science, University of Liverpool, Liverpool, UK
| |
Collapse
|
11
|
Smith AA, Lejeune A, Kow K, Milner RJ, Souza CH. Clinical Response and Adverse Event Profile of Bleomycin Chemotherapy for Canine Multicentric Lymphoma. J Am Anim Hosp Assoc 2017; 53:128-134. [DOI: 10.5326/jaaha-ms-6598] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
ABSTRACT
Although canine multicentric lymphoma is initially responsive to multidrug chemotherapy, resistance and relapse create a need for novel chemotherapeutics. Bleomycin is an antitumor antibiotic with a minimal adverse event profile; though commonly used for human non-Hodgkin's lymphoma, its use is poorly characterized in dogs. The purpose of this retrospective case series was to describe the clinical response and adverse event profile of systemic bleomycin for canine multicentric lymphoma (n = 10). A partial response was noted in one dog that died 24 days later due to unrelated disease. Adverse events were infrequent and limited to grade 1 gastrointestinal and grade 1 constitutional toxicity. Although clinical response was minimal, systemic bleomycin was well tolerated when administered at 0.5 U/kg. Additional studies are warranted to determine the influence of administration schedule and dose on the efficacy of bleomycin for veterinary neoplasia.
Collapse
Affiliation(s)
- Ashley A. Smith
- From the Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, Alabama (A.A.S.); Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida (A.L., C.H.M.S., R.J.M.); and Fitzpatrick Referrals, Godalming, Surrey, United Kingdom (K.K.)
| | - Amandine Lejeune
- From the Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, Alabama (A.A.S.); Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida (A.L., C.H.M.S., R.J.M.); and Fitzpatrick Referrals, Godalming, Surrey, United Kingdom (K.K.)
| | - Kelvin Kow
- From the Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, Alabama (A.A.S.); Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida (A.L., C.H.M.S., R.J.M.); and Fitzpatrick Referrals, Godalming, Surrey, United Kingdom (K.K.)
| | - Rowan J. Milner
- From the Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, Alabama (A.A.S.); Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida (A.L., C.H.M.S., R.J.M.); and Fitzpatrick Referrals, Godalming, Surrey, United Kingdom (K.K.)
| | - Carlos H.M. Souza
- From the Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, Alabama (A.A.S.); Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida (A.L., C.H.M.S., R.J.M.); and Fitzpatrick Referrals, Godalming, Surrey, United Kingdom (K.K.)
| |
Collapse
|
12
|
Childress MO, Ramos-Vara JA, Ruple A. A randomized controlled trial of the effect of prednisone omission from a multidrug chemotherapy protocol on treatment outcome in dogs with peripheral nodal lymphomas. J Am Vet Med Assoc 2016; 249:1067-1078. [DOI: 10.2460/javma.249.9.1067] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
13
|
Finotello R, Monné Rodriguez JM, Vilafranca M, Altimira J, Ramirez GA, Haines A, Ressel L. Immunohistochemical expression of MDR1-Pgp 170 in canine cutaneous and oral melanomas: pattern of expression and association with tumour location and phenotype. Vet Comp Oncol 2016; 15:1393-1402. [DOI: 10.1111/vco.12281] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2016] [Revised: 09/16/2016] [Accepted: 10/02/2016] [Indexed: 12/21/2022]
Affiliation(s)
- R. Finotello
- Small Animal Teaching Hospital, Institute of Veterinary Sciences; University of Liverpool; Neston UK
| | - J. M. Monné Rodriguez
- Section of Veterinary Pathology, Institute of Veterinary Sciences; University of Liverpool; Neston UK
| | - M. Vilafranca
- Laboratorio de Diagnóstico Histopatológico Histovet; Avda Països Catalans; Barcelona Spain
| | - J. Altimira
- Laboratorio de Diagnóstico Histopatológico Histovet; Avda Països Catalans; Barcelona Spain
| | - G. A. Ramirez
- Laboratorio de Diagnóstico Histopatológico Histovet; Avda Països Catalans; Barcelona Spain
| | - A. Haines
- Institute of Veterinary Sciences; University of Liverpool; Neston UK
| | - L. Ressel
- Section of Veterinary Pathology, Institute of Veterinary Sciences; University of Liverpool; Neston UK
| |
Collapse
|
14
|
Levi M, Brunetti B, Sarli G, Benazzi C. Immunohistochemical Expression of P-glycoprotein and Breast Cancer Resistance Protein in Canine Mammary Hyperplasia, Neoplasia and Supporting Stroma. J Comp Pathol 2016; 155:277-285. [PMID: 27528038 DOI: 10.1016/j.jcpa.2016.07.008] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2016] [Revised: 07/01/2016] [Accepted: 07/13/2016] [Indexed: 12/25/2022]
Abstract
The ability of a tumour to become simultaneously resistant to different drugs is known as multidrug resistance and is often due to the expression of ATP-dependent binding cassette transporters (ABC-transporters) such as P-glycoprotein (PGP) and breast cancer resistance protein (BCRP). In this study, the expression of PGP and BCRP was determined in the components of hyperplastic and neoplastic canine mammary glands, including the supporting stroma. The variation of expression of these molecules in carcinomas was evaluated between lesions of different histological stage and grade of malignancy. Samples included 47 hyperplastic tissues and 10 benign and 46 malignant neoplasms. Tumours were classified into histological subtype, histological stage and grade. Immunohistochemical evaluation of PGP and BCRP expression showed that both markers are potentially expressed by epithelial cells, myoepithelial cells in complex tumours and mesenchymal cells in mixed tumours, but expression of both proteins was significantly higher in malignant epithelial cells versus hyperplastic epithelium or the epithelium of benign tumours. BCRP showed significantly higher expression in epithelial cells of simple carcinomas versus those of complex and mixed carcinomas. Grade II and III carcinomas had higher epithelial PGP expression than grade I tumours. The positivity of stromal fibroblasts was higher in histological stage II versus I carcinomas, and in histological grade II versus I carcinomas. Malignant and invasive tumours were more likely to express PGP and/or BCRP in luminal and stromal components and evaluation of these markers could provide valuable information for the identification of tumours characterized by an aggressive and chemoresistant phenotype.
Collapse
Affiliation(s)
- M Levi
- Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy
| | - B Brunetti
- Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy.
| | - G Sarli
- Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy
| | - C Benazzi
- Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy
| |
Collapse
|
15
|
|
16
|
Flórez MM, Fêo HB, da Silva GN, Yamatogi RS, Aguiar AJ, Araújo JP, Rocha NS. Cell cycle kinetics, apoptosis rates and gene expressions of MDR-1, TP53, BCL-2 and BAX in transmissible venereal tumour cells and their association with therapy response. Vet Comp Oncol 2016; 15:793-807. [PMID: 26879698 DOI: 10.1111/vco.12220] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2015] [Revised: 01/06/2016] [Accepted: 01/12/2016] [Indexed: 12/17/2022]
Abstract
Transmissible venereal tumour (TVT) generally presents different degrees of aggressiveness, which makes them unresponsive to conventional treatment protocols. This implies a progressive alteration of their biological profile. This study aimed to evaluate the cytotoxicity, cell survival, apoptosis and cell cycle alterations in TVT cell cultures subjected to treatment with vincristine. Similarly, it assessed possible implications of MDR-1, TP53, BCL-2, and BAX gene expressions in eight TVT primary cultures for both resistance to chemotherapy and biological behaviour. When comparing TVT cells receiving vincristine to those untreated, a statistical difference related to increased cytotoxicity and decreased survival rates, and alterations in G1 and S cell cycle phases were found but without detectable differences in apoptosis. Increased MDR-1 gene expression was observed after treatment. The groups did not differ statistically in relation to the TP53, BAX and BCL-2 genes. Although preliminary, the findings suggest that such augmented expression is related to tumour malignancy and chemotherapy resistance.
Collapse
Affiliation(s)
- M M Flórez
- Department of Veterinary Clinics, Faculty of Veterinary Medicine, São Paulo State University-UNESP, Botucatu, Brazil.,Veterinary Pathology Research Group, Faculty of Agricultural Sciences, Universidad de Caldas, Manizales, Colombia
| | - H B Fêo
- Department of Veterinary Clinics, Faculty of Veterinary Medicine, São Paulo State University-UNESP, Botucatu, Brazil
| | - G N da Silva
- Department of Clinical Analysis. Pharmacy School, Universidade Federal de Ouro Preto, Ouro Preto, Brazil
| | - R S Yamatogi
- Department of Microbiology and immunology, Institute of Biosciences of Botucatu (IBB) and Biotechnology Institute (IBTEC), São Pablo State University-UNESP, Botucatu, Brazil
| | - A J Aguiar
- Department of Veterinary Clinics, Faculty of Veterinary Medicine, São Paulo State University-UNESP, Botucatu, Brazil
| | - J P Araújo
- Department of Microbiology and immunology, Institute of Biosciences of Botucatu (IBB) and Biotechnology Institute (IBTEC), São Pablo State University-UNESP, Botucatu, Brazil
| | - N S Rocha
- Department of Veterinary Clinics, Faculty of Veterinary Medicine, São Paulo State University-UNESP, Botucatu, Brazil
| |
Collapse
|
17
|
Visan S, Balacescu O, Berindan-Neagoe I, Catoi C. In vitro comparative models for canine and human breast cancers. ACTA ACUST UNITED AC 2016; 89:38-49. [PMID: 27004024 PMCID: PMC4777467 DOI: 10.15386/cjmed-519] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2015] [Accepted: 09/15/2015] [Indexed: 12/12/2022]
Abstract
During the past four decades, an increased number of similarities between canine mammary tumors and human breast cancer have been reported: molecular, histological, morphological, clinical and epidemiological, which lead to comparative oncological studies. One of the most important goals in human and veterinary oncology is to discover potential molecular biomarkers that could detect breast cancer in an early stage and to develop new effective therapies. Recently, cancer cell lines have successfully been used as an in vitro model to study the biology of cancer, to investigate molecular pathways and to test the efficiency of anticancer drugs. Moreover, establishment of an experimental animal model for the study of human breast cancer will improve testing potential anti-cancer therapies and the discovery of effective therapeutic schemes suitable for human clinical trials. In this review, we collected data from previous studies that strengthen the value of canine mammary cancer cell lines as an in vitro model for the study of human breast cancer.
Collapse
Affiliation(s)
- Simona Visan
- Department of Pathological Anatomy, Necropsy and Veterinary Forensic Medicine, Faculty of Veterinary Medicine, University of Agricultural Sciences and Veterinary Medicine, Cluj-Napoca, Romania; Department of Functional Genomics, Proteomics and Experimental Pathology, Prof. Dr. Ion Chiricuta Oncology Institute, Cluj-Napoca, Romania
| | - Ovidiu Balacescu
- Department of Functional Genomics, Proteomics and Experimental Pathology, Prof. Dr. Ion Chiricuta Oncology Institute, Cluj-Napoca, Romania
| | - Ioana Berindan-Neagoe
- Department of Functional Genomics, Proteomics and Experimental Pathology, Prof. Dr. Ion Chiricuta Oncology Institute, Cluj-Napoca, Romania; Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; Department of Immunology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, Texas, USA
| | - Cornel Catoi
- Department of Pathological Anatomy, Necropsy and Veterinary Forensic Medicine, Faculty of Veterinary Medicine, University of Agricultural Sciences and Veterinary Medicine, Cluj-Napoca, Romania
| |
Collapse
|
18
|
Mechanisms of Drug Resistance in Veterinary Oncology- A Review with an Emphasis on Canine Lymphoma. Vet Sci 2015; 2:150-184. [PMID: 29061939 PMCID: PMC5644636 DOI: 10.3390/vetsci2030150] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2015] [Revised: 07/22/2015] [Accepted: 08/04/2015] [Indexed: 01/09/2023] Open
Abstract
Drug resistance (DR) is the major limiting factor in the successful treatment of systemic neoplasia with cytotoxic chemotherapy. DR can be either intrinsic or acquired, and although the development and clinical implications are different, the underlying mechanisms are likely to be similar. Most causes for DR are pharmacodynamic in nature, result from adaptations within the tumor cell and include reduced drug uptake, increased drug efflux, changes in drug metabolism or drug target, increased capacity to repair drug-induced DNA damage or increased resistance to apoptosis. The role of active drug efflux transporters, and those of the ABC-transporter family in particular, have been studied extensively in human oncology and to a lesser extent in veterinary medicine. Methods reported to assess ABC-transporter status include detection of the actual protein (Western blot, immunohistochemistry), mRNA or ABC-transporter function. The three major ABC-transporters associated with DR in human oncology are ABCB1 or P-gp, ABCC1 or MRP1, and ABCG2 or BCRP, and have been demonstrated in canine cell lines, healthy dogs and dogs with cancer. Although this supports a causative role for these ABC-transporters in DR cytotoxic agents in the dog, the relative contribution to the clinical phenotype of DR in canine cancer remains an area of debate and requires further prospective studies.
Collapse
|
19
|
Tomiyasu H, Tsujimoto H. Comparative Aspects of Molecular Mechanisms of Drug Resistance through ABC Transporters and Other Related Molecules in Canine Lymphoma. Vet Sci 2015; 2:185-205. [PMID: 29061940 PMCID: PMC5644633 DOI: 10.3390/vetsci2030185] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2015] [Revised: 07/30/2015] [Accepted: 08/03/2015] [Indexed: 12/22/2022] Open
Abstract
The most important causes of treatment failure in canine lymphoma include intrinsic or acquired drug resistance. Thus, elucidation of molecular mechanisms of drug resistance is essential for the establishment of better treatment alternatives for lymphoma patients. The overexpression of drug transporters is one of the most intensively studied mechanisms of drug resistance in many tumors. In canine lymphoma, it has also been shown that the overexpression of drug efflux pumps such as P-glycoprotein is associated with drug-resistant phenotypes. Canine lymphoma has many pathological similarities to human non-Hodgkin’s lymphoma, and they also share similar molecular mechanisms of drug resistance. We have previously demonstrated the association of the overexpression of drug transporters with drug resistance and indicated some molecular mechanisms of the regulation of these transporters’ expressions in canine and human lymphoid tumor cells. However, it has also been indicated that other known or novel drug resistance factors should be explored to overcome drug resistance in lymphoma. In this review, we summarize the recent findings on the molecular mechanisms of drug resistance and possible strategies to develop better treatment modalities for canine lymphoma from the comparative aspects with human lymphoid tumors.
Collapse
Affiliation(s)
- Hirotaka Tomiyasu
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, 1352 Boyd Ave, St. Paul, MN 55108, USA.
- Masonic Cancer Center, University of Minnesota, Minneapolis, 420 Delaware Street SE, Minneapolis, MN 55455, USA.
| | - Hajime Tsujimoto
- Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.
| |
Collapse
|
20
|
A longitudinal study of ABC transporter expression in canine multicentric lymphoma. Vet J 2015; 205:263-71. [DOI: 10.1016/j.tvjl.2014.11.002] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2014] [Revised: 10/29/2014] [Accepted: 11/05/2014] [Indexed: 12/18/2022]
|
21
|
Asada H, Tomiyasu H, Goto-Koshino Y, Fujino Y, Ohno K, Tsujimoto H. Evaluation of the drug sensitivity and expression of 16 drug resistance-related genes in canine histiocytic sarcoma cell lines. J Vet Med Sci 2015; 77:677-84. [PMID: 25715778 PMCID: PMC4488404 DOI: 10.1292/jvms.14-0415] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Canine histiocytic sarcoma (HS) is an aggressive tumor type originating from histiocytic
cell lineages. This disease is characterized by poor response to chemotherapy and short
survival time. Therefore, it is of critical importance to identify and develop effective
antitumor drugs against HS. The objectives of this study were to examine the drug
sensitivities of 10 antitumor drugs. Using a real-time RT-PCR system, the mRNA expression
levels of 16 genes related to drug resistance in 4 canine HS cell lines established from
dogs with disseminated HS were determined and compared to 2 canine lymphoma cell lines
(B-cell and T-cell). These 4 canine HS cell lines showed sensitivities toward microtubule
inhibitors (vincristine, vinblastine and paclitaxel), comparable to those in the canine
B-cell lymphoma cell line. Moreover, it was shown that P-gp in the HS cell lines used in
this study did not have enough function to efflux its substrate. Sensitivities to
melphalan, nimustine, methotrexate, cytarabine, doxorubicin and etoposide were lower in
the 4 HS cell lines than in the 2 canine lymphoma cell lines. The data obtained in this
study using cultured cell lines could prove helpful in the developing of advanced and
effective chemotherapies for treating dogs that are suffering from HS.
Collapse
Affiliation(s)
- Hajime Asada
- Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Science, The University of Tokyo, Bunkyo-ku, Tokyo 113-8657, Japan
| | | | | | | | | | | |
Collapse
|
22
|
Zandvliet M, Teske E, Schrickx J. Multi-drug resistance in a canine lymphoid cell line due to increased P-glycoprotein expression, a potential model for drug-resistant canine lymphoma. Toxicol In Vitro 2014; 28:1498-506. [DOI: 10.1016/j.tiv.2014.06.004] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2014] [Revised: 03/13/2014] [Accepted: 06/19/2014] [Indexed: 10/25/2022]
|
23
|
Tomiyasu H, Fujiwara-Igarashi A, Goto-Koshino Y, Fujino Y, Ohno K, Tsujimoto H. Evaluation of DNA methylation profiles of the CpG island of the ABCB1 gene in dogs with lymphoma. Am J Vet Res 2014; 75:835-41. [PMID: 25157887 DOI: 10.2460/ajvr.75.9.835] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To examine the DNA methylation status of the ABCB1 gene in tumor cells of dogs with lymphoma. ANIMALS 27 dogs with multicentric B-cell high-grade lymphoma (19 chemotherapy-sensitive dogs and 8 chemotherapy-resistant dogs). PROCEDURES The DNA methylation profile of the CpG island of the ABCB1 gene was analyzed by use of bisulphite sequencing and real-time methylation-specific PCR assay in lymphoma cells. Quantitative reverse transcriptase PCR assay of the ABCB1 gene was conducted to measure the amount of mRNA. Correlation between the amount of ABCB1 mRNA and the methylation rate was examined. RESULTS The CpG island of the ABCB1 gene was hypomethylated in most dogs in both the chemotherapy-sensitive and -resistant groups. No significant difference was detected in the methylation rate between the 2 groups, and no significant correlation was detected between the methylation rate and the mRNA expression level. CONCLUSIONS AND CLINICAL RELEVANCE Expression of the ABCB1 gene was not suppressed by hypermethylation of its CpG island in most dogs with lymphoma regardless of their chemotherapy sensitivity status.
Collapse
Affiliation(s)
- Hirotaka Tomiyasu
- Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | | | | | | | | | | |
Collapse
|
24
|
Saeed M, Zeino M, Kadioglu O, Volm M, Efferth T. Overcoming of P-glycoprotein-mediated multidrug resistance of tumors in vivo by drug combinations. ACTA ACUST UNITED AC 2014. [DOI: 10.1016/j.synres.2014.07.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
|
25
|
Tomiyasu H, Goto-Koshino Y, Fujino Y, Ohno K, Tsujimoto H. Antitumour effect and modulation of expression of the ABCB1 gene by perifosine in canine lymphoid tumour cell lines. Vet J 2014; 201:83-90. [DOI: 10.1016/j.tvjl.2014.04.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2013] [Revised: 03/04/2014] [Accepted: 04/02/2014] [Indexed: 10/25/2022]
|
26
|
Tomiyasu H, Goto-Koshino Y, Fujino Y, Ohno K, Tsujimoto H. Epigenetic regulation of the ABCB1 gene in drug-sensitive and drug-resistant lymphoid tumour cell lines obtained from canine patients. Vet J 2014; 199:103-9. [DOI: 10.1016/j.tvjl.2013.10.022] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2013] [Revised: 10/03/2013] [Accepted: 10/18/2013] [Indexed: 10/26/2022]
|
27
|
Gerardi DG, Tinucci-Costa M, Silveira ACT, Moro JV. Expression of P-glycoprotein, multidrug resistance-associated protein, glutathione-S-transferase pi and p53 in canine transmissible venereal tumor. PESQUISA VETERINARIA BRASILEIRA 2014. [DOI: 10.1590/s0100-736x2014000100012] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The overexpression of proteins P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP1), mutant p53, and the enzyme glutathione-S-transferase (GSTpi) are related to resistance to chemotherapy in neoplasms. This study evaluated the expression of these markers by immunohistochemistry in two groups of canine TVT, without history of prior chemotherapy (TVT1, n=9) and in TVTs presented unsatisfactory clinical response to vincristine sulfate (TVT2, n=5). The percentage of specimens positively stained for P-gp, MRP1, GSTpi and p53 were, respectively 88.8%, 0%, 44.5% and 22.2% in TVT1 and 80%, 0%, 80% and 0% in TVT2. In TVT1, one specimen presented positive expression for three markers and four specimens for two markers. In TVT2, three specimens expressed P-gp and GSTpi. In conclusion, the canine TVTs studied expressed the four markers evaluated, but just P-gp and GSTpi were significantly expressed, mainly at cytoplasm and cytoplasm and nuclei, respectively, either before chemotherapy as after vincristine sulfate exposure. Future studies are needed to demonstrate the function of these two markers in conferring multidrug resistance (MDR) or predict the response to chemotherapy in canine TVT.
Collapse
|
28
|
Tomiyasu H, Goto-Koshino Y, Fujino Y, Ohno K, Tsujimoto H. The regulation of the expression of ABCG2 gene through mitogen-activated protein kinase pathways in canine lymphoid tumor cell lines. J Vet Med Sci 2013; 76:237-42. [PMID: 24161965 PMCID: PMC3982807 DOI: 10.1292/jvms.13-0337] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
Treatments for canine lymphoma often fail, because tumor cells acquire multidrug resistance (MDR). MDR can develop through several mechanisms, among which the overexpression of drug transporters in tumor cells is a well-studied mechanism. ATP-binding cassette sub-family G member 2 (ABCG2) belongs to the ABC-transporters, that are representative drug efflux pumps associated with MDR in human tumor cells. However, the regulation of ABCG2 gene expression in canine tumors is not well understood. The purpose of the present study was to reveal the regulatory mechanism of ABCG2 gene expression in 4 canine lymphoid tumor cell lines, GL-1, CLBL-1, UL-1 and Ema. Treatment with phorbol 12-myristate 13-acetate (PMA), the protein kinase C (PKC) activator, stimulated MAPK/ERK pathway in GL-1, UL-1 and Ema cells and JNK pathway in UL-1 and Ema cells. When GL-1 and UL-1 cells were treated with PMA and the MAPK/ERK kinase inhibitor U0126, ABCG2 gene expression levels were elevated above those in untreated cells. Similarly, ABCG2 gene expression increased above control levels in UL-1 and Ema cells treated with PMA and the JNK inhibitor SP600125. However, ABCG2 gene expression was unaffected by U0126 exposure in CLBL-1 cells, in which activation of MAPK/ERK pathway was observed in non-treated cells. These results suggested that MAPK/ERK and JNK pathways downregulate ABCG2 gene expression, which is upregulated by unidentified but possibly PKC-dependent pathways, in several types of canine lymphoid tumor cells.
Collapse
Affiliation(s)
- Hirotaka Tomiyasu
- Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | | | | | | | | |
Collapse
|
29
|
Zandvliet M, Rutteman G, Teske E. Prednisolone inclusion in a first-line multidrug cytostatic protocol for the treatment of canine lymphoma does not affect therapy results. Vet J 2013; 197:656-61. [DOI: 10.1016/j.tvjl.2013.04.022] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2013] [Revised: 03/25/2013] [Accepted: 04/29/2013] [Indexed: 11/26/2022]
|
30
|
Back AR, Schleis SE, Smrkovski OA, Lee J, Smith AN, Phillips JC. Mechlorethamine, vincristine, melphalan and prednisone (MOMP) for the treatment of relapsed lymphoma in dogs. Vet Comp Oncol 2013; 13:398-408. [PMID: 23910023 DOI: 10.1111/vco.12055] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2013] [Revised: 06/18/2013] [Accepted: 06/18/2013] [Indexed: 12/20/2022]
Abstract
Eighty-eight dogs with relapsed lymphoma were treated with the MOMP (mechlorethamine, vincristine, melphalan and prednisone) protocol on a 28-day treatment cycle. The overall response rate (ORR) to the MOMP protocol was 51.1% for a median of 56 days (range 7-858 days). Twelve percent of dogs experienced a complete response for a median of 81 days (range 42-274 days) and 38.6% experienced a partial response for a median of 49 days (range 7-858 days). Dogs with T-cell lymphoma had an ORR of 55% for a median of 60 days (range 49-858 days) while those with B-cell lymphoma had an ORR of 57% for a median of 81 days (range 7-274 days) (P = 0.783). The overall survival time for all dogs was 183 days (range 17-974 days). Fifty-four percent of dogs experienced toxicity with the majority classified as grade I. The MOMP protocol seems well-tolerated and is an option for dogs with relapsed lymphoma.
Collapse
Affiliation(s)
- A R Back
- Comparative Oncology Program, Department of Clinical Sciences, Auburn University, College of Veterinary Medicine, Auburn, AL, USA
| | - S E Schleis
- Comparative Oncology Program, Department of Clinical Sciences, Auburn University, College of Veterinary Medicine, Auburn, AL, USA
| | - O A Smrkovski
- Comparative Oncology Program, Department of Small Animal Medicine, University of Tennessee, College of Veterinary Medicine, Knoxville, TN, USA
| | - J Lee
- Comparative Oncology Program, Department of Small Animal Medicine, University of Tennessee, College of Veterinary Medicine, Knoxville, TN, USA
| | - A N Smith
- Comparative Oncology Program, Department of Clinical Sciences, Auburn University, College of Veterinary Medicine, Auburn, AL, USA
| | - J C Phillips
- Animal Emergency Critical Care and Referral Center, Knoxville, TN, USA
| |
Collapse
|
31
|
Gramer I, Kessler M, Geyer J. Determination of MDR1 gene expression for prediction of chemotherapy tolerance and treatment outcome in dogs with lymphoma. Vet Comp Oncol 2013; 13:363-72. [PMID: 23834200 DOI: 10.1111/vco.12051] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2013] [Accepted: 05/29/2013] [Indexed: 11/28/2022]
Abstract
The multidrug resistance gene 1(MDR1) expression levels were analysed in 27 dogs with different types of malignant lymphomas receiving a standard chemotherapy protocol. Blood samples were used for MDR1 real-time PCR expression analysis. Treatment tolerance and outcome were evaluated on a regular basis by clinical examination and client questioning. Dogs developing severe adverse effects under treatment showed significantly lower basal MDR1 gene expression levels when compared with those who tolerated the drugs well. In the longitudinal MDR1 gene expression analysis during treatment, four dogs showed a greater than two-fold MDR1 up-regulation, compared to baseline expression. All four of these dogs, but none of the others, showed disease progression. In conclusion, basal and follow-up MDR1 gene expression levels could be of predictive value for the occurrence of severe adverse drug reactions and/or the development of MDR during chemotherapy for lymphoma in dogs.
Collapse
Affiliation(s)
- I Gramer
- Institute of Pharmacology and Toxicology, Justus Liebig University of Giessen, Giessen, Germany.,Hofheim Animal Hospital, Hofheim am Taunus, Germany
| | - M Kessler
- Hofheim Animal Hospital, Hofheim am Taunus, Germany
| | - J Geyer
- Institute of Pharmacology and Toxicology, Justus Liebig University of Giessen, Giessen, Germany
| |
Collapse
|
32
|
Dhaliwal RS, Kitchell BE, Ehrhart EJ, Valli VE, Dervisis NG. Clinicopathologic Significance of Histologic Grade, Pgp, and P53 Expression in Canine Lymphoma. J Am Anim Hosp Assoc 2013; 49:175-84. [DOI: 10.5326/jaaha-ms-5843] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
To characterize the expression of P-glycoprotein (Pgp) and p53 in different histologic grades of canine multicentric lymphosarcoma (LSA), 31 cases of LSA without prior treatment were studied. The expression levels of the Pgp and p53 proteins were evaluated for their clinicopathologic significance among standard histologic evaluation. Immunohistochemistry (IHC) was performed on formalin-fixed, paraffin-embedded archival samples of 31 previously untreated LSA cases to detect the expression of Pgp and p53. All dogs were subsequently treated with a combination chemotherapy protocol. Remission and survival durations were evaluated for correlation with histologic grade and presence of drug resistance markers. Of the 31 cases, 24 (80%) and 7 (22%) were positive for Pgp and p53, respectively. Overall, the median survival and duration of remission in the study was 246 days and 137 days, respectively. The National Cancer Institute working formulation histologic grade was not associated with either survival or duration of first remission (DOR). The Pgp protein expression and DOR and survival was not statistically significant. Expression of p53 was statistically correlated with survival.
Collapse
Affiliation(s)
- Ravinder S. Dhaliwal
- Center for Comparative Oncology, Michigan State University, East Lansing, MI (B.K., N.D.); Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO (E.E.); and VDx Veterinary Diagnostics, Davis, CA (V.V.)
| | - Barbara E. Kitchell
- Center for Comparative Oncology, Michigan State University, East Lansing, MI (B.K., N.D.); Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO (E.E.); and VDx Veterinary Diagnostics, Davis, CA (V.V.)
| | - EJ Ehrhart
- Center for Comparative Oncology, Michigan State University, East Lansing, MI (B.K., N.D.); Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO (E.E.); and VDx Veterinary Diagnostics, Davis, CA (V.V.)
| | - Victor E. Valli
- Center for Comparative Oncology, Michigan State University, East Lansing, MI (B.K., N.D.); Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO (E.E.); and VDx Veterinary Diagnostics, Davis, CA (V.V.)
| | - Nikolaos G. Dervisis
- Center for Comparative Oncology, Michigan State University, East Lansing, MI (B.K., N.D.); Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO (E.E.); and VDx Veterinary Diagnostics, Davis, CA (V.V.)
| |
Collapse
|
33
|
Zandvliet M, Teske E, Chapuis T, Fink-Gremmels J, Schrickx JA. Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein. J Vet Pharmacol Ther 2013; 36:583-7. [DOI: 10.1111/jvp.12039] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2012] [Accepted: 01/09/2013] [Indexed: 12/01/2022]
Affiliation(s)
- M. Zandvliet
- Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine; Utrecht University; Utrecht The Netherlands
| | - E. Teske
- Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine; Utrecht University; Utrecht The Netherlands
| | | | - J. Fink-Gremmels
- IRAS Veterinary Pharmacology, Pharmacotherapy and Toxicology, Faculty of Veterinary Medicine; Utrecht University; Utrecht The Netherlands
| | - J. A. Schrickx
- IRAS Veterinary Pharmacology, Pharmacotherapy and Toxicology, Faculty of Veterinary Medicine; Utrecht University; Utrecht The Netherlands
| |
Collapse
|
34
|
Hematopoietic Tumors. WITHROW AND MACEWEN'S SMALL ANIMAL CLINICAL ONCOLOGY 2013. [PMCID: PMC7161412 DOI: 10.1016/b978-1-4377-2362-5.00032-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
35
|
Kim NH, Hwang YH, Im KS, Kim JH, Chon SK, Kim HY, Sur JH. P-glycoprotein expression in canine mammary gland tumours related with myoepithelial cells. Res Vet Sci 2012; 93:1346-52. [DOI: 10.1016/j.rvsc.2012.04.004] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2012] [Accepted: 04/08/2012] [Indexed: 11/28/2022]
|
36
|
Teng SP, Hsu WL, Chiu CY, Wong ML, Chang SC. Overexpression of P-glycoprotein, STAT3, phospho-STAT3 and KIT in spontaneous canine cutaneous mast cell tumours before and after prednisolone treatment. Vet J 2012; 193:551-6. [PMID: 22398132 DOI: 10.1016/j.tvjl.2012.01.033] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2011] [Revised: 01/29/2012] [Accepted: 01/30/2012] [Indexed: 10/28/2022]
Abstract
Prednisolone is a glucocorticoid (GC) commonly used in the treatment of canine mast cell tumours (MCTs); however, resistance to GCs develops in many MCTs following repeated treatment. P-glycoprotein (P-gp), signal transducer and activator of transcription 3 (STAT3) and KIT (CD117) are involved in GC resistance. The aim of this study was to evaluate the response to prednisolone treatment in canine cutaneous MCTs and to investigate the levels of P-gp, STAT3, phospho-STAT3 (pSTAT3) and KIT proteins in MCTs with or without prednisolone treatment. Immunohistochemistry was performed on tumour samples from 41 dogs with cutaneous MCTs. The overall objective response rate (including complete and partial responses) was 51.8% for dogs treated with prednisolone; poorly differentiated or higher stage MCTs had a lower response rate. The median time-span of tumours to reach maximal tumour regression was 14 d (range 3-77 d); 22 (81.5%) reached maximal regression at 21 d. The majority of MCTs overexpressed both P-gp and STAT3 before and after prednisolone treatment. Reduced expression of pSTAT3 and alterations in the KIT expression pattern were observed in MCTs post-treatment. Prednisolone treatment that caused a marked reduction in tumour volume was correlated with reduced pSTAT3 expression. A cytoplasmic KIT staining pattern was correlated with a lower tumour response rate to prednisolone treatment.
Collapse
Affiliation(s)
- Shr-Ping Teng
- Department of Veterinary Medicine, College of Veterinary Medicine, National Chung Hsing University, Taichung 40227, Taiwan
| | | | | | | | | |
Collapse
|
37
|
Flood-Knapik KE, Durham AC, Gregor TP, Sánchez MD, Durney ME, Sorenmo KU. Clinical, histopathological and immunohistochemical characterization of canine indolent lymphoma. Vet Comp Oncol 2012; 11:272-86. [DOI: 10.1111/j.1476-5829.2011.00317.x] [Citation(s) in RCA: 79] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- K. E. Flood-Knapik
- Matthew J. Ryan Veterinary Hospital; University of Pennsylvania School of Veterinary Medicine; Philadelphia PA 19104-6010 USA
| | - A. C. Durham
- Matthew J. Ryan Veterinary Hospital; University of Pennsylvania School of Veterinary Medicine; Philadelphia PA 19104-6010 USA
| | - T. P. Gregor
- Matthew J. Ryan Veterinary Hospital; University of Pennsylvania School of Veterinary Medicine; Philadelphia PA 19104-6010 USA
| | - M. D. Sánchez
- Matthew J. Ryan Veterinary Hospital; University of Pennsylvania School of Veterinary Medicine; Philadelphia PA 19104-6010 USA
| | - M. E. Durney
- Matthew J. Ryan Veterinary Hospital; University of Pennsylvania School of Veterinary Medicine; Philadelphia PA 19104-6010 USA
| | - K. U. Sorenmo
- Matthew J. Ryan Veterinary Hospital; University of Pennsylvania School of Veterinary Medicine; Philadelphia PA 19104-6010 USA
| |
Collapse
|
38
|
Fahey CE, Milner RJ, Barabas K, Lurie D, Kow K, Parfitt S, Lyles S, Clemente M. Evaluation of the University of Florida lomustine, vincristine, procarbazine, and prednisone chemotherapy protocol for the treatment of relapsed lymphoma in dogs: 33 cases (2003-2009). J Am Vet Med Assoc 2011; 239:209-15. [PMID: 21756176 DOI: 10.2460/javma.239.2.209] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To evaluate the toxicity and efficacy of a modification of a previously evaluated combination of lomustine, vincristine, procarbazine, and prednisone (LOPP) as a rescue protocol for refractory lymphoma in dogs. DESIGN Retrospective case series. Animals-33 dogs with a cytologic or histologic diagnosis of lymphoma that developed resistance to their induction chemotherapy protocol. PROCEDURES Lomustine was administered on day 0 of the protocol. Vincristine was administered on day 0 and again 1 time on day 14. Procarbazine and prednisone were administered on days 0 through 13 of the protocol. This cycle was repeated every 28 days. RESULTS Median time from initiation to discontinuation of the University of Florida LOPP protocol was 84 days (range, 10 to 308 days). Overall median survival time was 290 days (range, 51 to 762 days). Overall response rate with this protocol was 61% (20/33), with 36% (12) having a complete response and 24% (8) having a partial response. Toxicosis rates were lower than for the previously published LOPP protocol. CONCLUSIONS AND CLINICAL RELEVANCE The University of Florida LOPP protocol may be an acceptable alternative to the mechlorethamine, vincristine, procarbazine, and prednisone protocol as a rescue protocol for dogs with lymphoma.
Collapse
Affiliation(s)
- Christine E Fahey
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL 32610, USA
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Van der Heyden S, Chiers K, Vercauteren G, Daminet S, Wegge B, Paepe D, Ducatelle R. Expression of Multidrug Resistance-Associated P-Glycoprotein in Feline Tumours. J Comp Pathol 2011; 144:164-9. [DOI: 10.1016/j.jcpa.2010.08.008] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2010] [Revised: 06/07/2010] [Accepted: 08/12/2010] [Indexed: 11/27/2022]
|
40
|
Honscha KU, Schirmer A, Reischauer A, Schoon HA, Einspanier A, Gäbel G. Expression of ABC-transport proteins in canine mammary cancer: consequences for chemotherapy. Reprod Domest Anim 2010; 44 Suppl 2:218-23. [PMID: 19754573 DOI: 10.1111/j.1439-0531.2009.01382.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Intrinsic or acquired drug resistance is a major barrier for chemotherapy of cancer. Importantly, the presence of ATP-binding cassette, ABC-transport proteins in tumour cells circumvents an intracellular accumulation of chemotherapeutic drugs. In this study, 103 canine mammary tumour probes were investigated for mRNA expression of seven ABC-transporters by RT-PCR. All tumour samples expressed multidrug resistance-associated protein 1 (MRP1) and breast cancer resistance protein (BCRP). MRP7 was detected in 97.1% of tumour probes, MRP3 in 96.1%, Pgp in 92.2%, MRP5 in 85.4% and MRP6 in 64.1%. More of the half of tumour samples (56.1%) expressed all of the examined ABC-transport proteins. Approximately one-third of the tumour samples (32.7%) were lacking in one transporter and only 11.2% possessed from three to five transporters. The canine transporter cBCRP was functionally analysed in stable transfected Madin-Darby canine kidney-II cells using an MTT viability test. cBCRP transfected cells showed a 5.4-fold resistance to 10 microm doxorubicin. Cell survival in the presence of methotrexate was not affected by cBCRP. In conclusion, absence of efficiency of chemotherapy of canine mammary cancer can be caused by expression of seven various ABC-transport proteins. Because cBCRP is expressed in all examined tumour probes and induces resistance to doxorubicin, the application of doxorubicin for treatment of canine mammary is inappropriate.
Collapse
Affiliation(s)
- K U Honscha
- Institute of Veterinary Physiology, Faculty of Veterinary Medicine, University of Leipzig, Leipzig, Germany.
| | | | | | | | | | | |
Collapse
|
41
|
Saba C, Hafeman S, Vail D, Thamm D. Combination Chemotherapy with Continuous l-Asparaginase, Lomustine, and Prednisone for Relapsed Canine Lymphoma. J Vet Intern Med 2009; 23:1058-63. [DOI: 10.1111/j.1939-1676.2009.0357.x] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
42
|
LEBLANC AMYK, JAKOBY BJOERNW, TOWNSEND DAVIDW, DANIEL GREGORYB. 18FDG-PET IMAGING IN CANINE LYMPHOMA AND CUTANEOUS MAST CELL TUMOR. Vet Radiol Ultrasound 2009; 50:215-23. [DOI: 10.1111/j.1740-8261.2009.01520.x] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
43
|
Schleis SE, LeBlanc AK, Neilsen NR, LeBlanc CJ. Flow cytometric evaluation of multidrug resistance proteins on grossly normal canine nodal lymphocyte membranes. Am J Vet Res 2008; 69:1310-5. [DOI: 10.2460/ajvr.69.10.1310] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
44
|
Brenn SH, Couto SS, Craft DM, Leung C, Bergman PJ. Evaluation of P-glycoprotein expression in feline lymphoma and correlation with clinical outcome. Vet Comp Oncol 2008; 6:201-11. [DOI: 10.1111/j.1476-5829.2008.00161.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
45
|
Lurie DM, Milner RJ, Suter SE, Vernau W. Immunophenotypic and cytomorphologic subclassification of T-cell lymphoma in the boxer breed. Vet Immunol Immunopathol 2008; 125:102-10. [PMID: 18579219 DOI: 10.1016/j.vetimm.2008.05.009] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2008] [Revised: 04/29/2008] [Accepted: 05/08/2008] [Indexed: 01/22/2023]
Abstract
The boxer breed is at high risk for developing lymphoma and, in contrast to the general canine population, is predisposed to the T-cell variant of the disease. The purpose of this study was to more accurately classify lymphoma in this breed. Clinical, cytomorphologic and immunophenotypic data were examined in 43 boxers with lymphoma. Twenty-five cases were collected prospectively and a further 18 cases were obtained retrospectively. Lymphomas were classified as multicentric (n=29), mediastinal (n=6) and intestinal (n=8). Of the 40 immunophenotyped samples, 34 (85%) were T-cell, 5 (12.5%) were B-cell and 1 was a non-B-cell non-T-cell lymphoma. Immunophenotypic subtyping was done on prospectively collected T-cell lymphoma samples (n=22) to differentiate CD4 (helper) from CD8 (cytotoxic) T-cell origin as well as to determine the T-cell receptor (TCR) expression (TCRalphabeta vs. TCRdeltagamma). Phenotypic expression was CD4+ (n=12), double negative (DN) (n=6), double positive (DP) (n=1) and CD8+ (n=1), respectively, while two samples had no interpretable result. 20/22 samples were TCRalphabeta+ with only 1 sample being TCRdeltagamma+ and 1 with no interpretable result. Cytomorphologic analysis was done on the same 22 samples using the World Health Organization (WHO) classification scheme. According to this scheme, 17/22 samples were classified as lymphoblastic, 2/22 as large cell peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), 2/22 as large granular lymphoma (LGL) high-grade and 1/22 as small lymphocytic. The results of this study indicate that lymphoma in the boxer breed is a disease comprised predominantly of TCRalphabeta+, CD4+ (helper) T-cells with lymphoblastic (high-grade) morphology.
Collapse
Affiliation(s)
- David M Lurie
- Department of Small Animal Clinical Sciences, University of Florida, Gainesville, FL 32610, USA.
| | | | | | | |
Collapse
|
46
|
Implications of ABC transporters on the disposition of typical veterinary medicinal products. Eur J Pharmacol 2008; 585:510-9. [PMID: 18417119 DOI: 10.1016/j.ejphar.2008.03.014] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2008] [Revised: 02/21/2008] [Accepted: 03/03/2008] [Indexed: 01/16/2023]
Abstract
The ATP-Binding Cassette (ABC) transporters ABCB1, ABCC2 and ABCG2 are efflux transporters that facilitate the excretion of drugs, contribute to the function of biological barriers and maintain low cytoplasmic substrate concentrations in cells. ABC transporters modulate drug absorption, distribution and elimination according to the level of expression in the intestine, liver, kidney, and at biological barriers such as the blood-brain barrier. Moreover individual transporters are known to convey multi-drug resistance to tumour cells. While these diverse functions have been described in laboratory animal studies and in humans, the available information is very limited in animal species that are typical veterinary patients. This brief review summarizes the available data on organ distribution and expression levels in animals, genetic defects in dogs resulting in a non-functional P-gp expression, and describes examples of kinetic investigations directed to assess the clinical relevance of species differences in ABC-transporter expression.
Collapse
|
47
|
Nakaichi M, Takeshita Y, Okuda M, Nakamoto Y, Itamoto K, Une S, Sasaki N, Kadosawa T, Takahashi T, Taura Y. Expression of the MDR1 gene and P-glycoprotein in canine mast cell tumor cell lines. J Vet Med Sci 2007; 69:111-5. [PMID: 17339753 DOI: 10.1292/jvms.69.111] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Cellular drug resistance to antineoplastic drugs is often due to the presence of a drug efflux pump that reduces intracellular drug accumulation and chemosensitivity. P-glycoprotein (P-gp), which is encoded by the MDR1 gene, is considered to function as an ATP-driven membrane drug efflux pump and appears to play an important role in tumor cell resistance. In the present report, we assessed the expression of MDR1 by RT-PCR in three canine mast cell tumor cell lines, TiMC, CoMS and LuMC, originating from a cutaneous tumor, an oral-mucosal tumor and a gastrointestinal tumor, respectively. P-gp expression was also examined by Western blot analysis, while the functional activity of P-gp was assessed by flowcytometric analysis of intracellular rhodamine-123 (Rhd-123) uptake. The results revealed that MDR1 gene and P-gp were both expressed in CoMS and LuMC cells, whereas neither was present in TiMC cells. In CoMS and LuMC cells, intracellular uptake of Rhd-123 increased in the presence of verapamil, a functional modulator of P-gp. In contrast, TiMC cells did not show any changes in the intracellular accumulation of Rhd-123 after the verapamil addition. These findings suggest that the expressions of MDR1 gene and P-gp probably contribute to cellular drug resistance in canine mast cell tumors.
Collapse
Affiliation(s)
- Munekazu Nakaichi
- Department of Veterinary Surgery, Yamaguchi University, Yoshida, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Matsuura S, Koto H, Ide K, Fujino Y, Setoguchi-Mukai A, Ohno K, Tsujimoto H. Induction of chemoresistance in a cultured canine cell line by retroviral transduction of the canine multidrug resistance 1 gene. Am J Vet Res 2007; 68:95-100. [PMID: 17199425 DOI: 10.2460/ajvr.68.1.95] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To induce chemoresistance in a normal canine cell line through the transduction of the canine multidrug resistance 1 gene (mdr1). SAMPLE POPULATION Madin-Darby canine kidney (MDCK) epithelial cell line. PROCEDURES The full-length canine mdr1 cDNA clone isolated in our laboratory was inserted into a Moloney murine leukemia virus-based vector to construct the retroviral vector, pLNC-cMDR1. After retroviral transduction of pLNC-cMDR1 into MDCK cells, the expression and function of the P-glycoprotein, a product of mdr1, were assessed by immunoblotting, measurement of rhodamine123 (Rh123) retention, and drug sensitivity assays. RESULTS P-glycoprotein was strongly expressed in cells transduced with pLNC-cMDR1. This P-glycoprotein was fully functional, as demonstrated by the decreased Rh123 retention and the increased resistance to chemotherapeutic drugs. Measured as 50% inhibitory concentrations, resistance increased 59 times to vincristine and 25 times to doxorubicin in MDCK cells after transduction of pLNC-cMDR1. CONCLUSIONS AND CLINICAL RELEVANCE Transduction of canine mdr1 is an effective method for inducing chemoresistance in normal canine cells. This system may be applicable to the induction of drug resistance in hematopoietic cells.
Collapse
MESH Headings
- ATP Binding Cassette Transporter, Subfamily B, Member 1/biosynthesis
- ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics
- ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism
- Animals
- Antineoplastic Agents/pharmacology
- Base Sequence
- COS Cells
- Cell Line
- Chlorocebus aethiops
- DNA, Complementary/genetics
- Dogs/genetics
- Dogs/metabolism
- Doxorubicin/pharmacology
- Drug Resistance, Neoplasm
- Flow Cytometry/veterinary
- Fluorescent Dyes/metabolism
- Genetic Vectors/genetics
- Inhibitory Concentration 50
- Molecular Sequence Data
- Retroviridae/genetics
- Rhodamine 123/metabolism
- Sequence Analysis, DNA
- Transduction, Genetic/veterinary
- Vincristine/pharmacology
Collapse
Affiliation(s)
- Shinobu Matsuura
- Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo 113-8657, Japan
| | | | | | | | | | | | | |
Collapse
|
49
|
Wijewardana V, Sugiura K, Oichi T, Fujimoto M, Akazawa T, Hatoya S, Inaba M, Ikehara S, Jayaweera TSP, Inaba T. Generation of canine dendritic cells from peripheral blood monocytes without using purified cytokines. Vet Immunol Immunopathol 2006; 114:37-48. [PMID: 16904755 DOI: 10.1016/j.vetimm.2006.07.002] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2006] [Revised: 06/29/2006] [Accepted: 07/05/2006] [Indexed: 01/06/2023]
Abstract
Dendritic cells (DCs), which differentiate in vitro from peripheral blood monocytes (PBMOs) or bone marrow precursors, are a promising candidate for immunotherapy against cancer. The dog, which suffers common types of cancers along with humans, make an ideal large animal model for cancer studies. Monocyte-derived DCs in the dog have not been well characterized, however, since the appropriate condition for in vitro differentiation has not been established. To tackle this problem, we have developed a conditioned media by culturing T cells with immobilized anti-canine CD3 antibody, and sought to induce differentiation of DCs from PBMOs. When purified CD14+ PBMOs were cultured in the presence of 25% T cell conditioned medium (TCCM), the PBMOs increased size and had extended dendritic processes by day 12 of the culture. The cultured PBMOs were found to increase the expression of MHC class II and CD1a molecules, and significantly increased stimulatory activity for allogeneic T cells in the mixed leukocyte reaction. Moreover, the cells significantly increased their expression of IL-18 and IFN-gamma when stimulated with polyinosinic-polycytidylic acid (Poly (I:C)). The cells have a reduced phagocytic activity, which is a common defect in mature DCs. It follows from these results that TCCM does induce the differentiation of DCs from PBMOs.
Collapse
Affiliation(s)
- Viskam Wijewardana
- Department of Advanced Pathobiology, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, 1-1 Gakuen-cho, Naka-ku, Sakai City, Osaka 599-8531, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
KWAK J, PAGE R, WHITE M, LAHUNTA AD, DIVERS TJ, MOHAMMED HO. Immunohistochemical Detection of P-glycoprotein in Tissues from Horses Afflicted with Equine Motor Neuron Disease. J Equine Sci 2006. [DOI: 10.1294/jes.17.1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Affiliation(s)
- Justin KWAK
- Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University
| | - Rodney PAGE
- Department of Clinical Sciences, College of Veterinary Medicine, Cornell University
| | - Maurice WHITE
- Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University
| | - Alexander de LAHUNTA
- Department Biomedical Science, College of Veterinary Medicine, Cornell University
| | - Thomas J. DIVERS
- Department of Clinical Sciences, College of Veterinary Medicine, Cornell University
| | - Hussni O. MOHAMMED
- Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University
| |
Collapse
|